Company profile: Angiolink
1.1 - Company Overview
Company description
- Provider of vascular closure solutions for catheter-based procedures, offering the EVS vascular closure system, an arterial stapling device designed to close holes and punctures in arteries following procedures such as angioplasty and angiograms.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Angiolink
Thrombolex
HQ: United States
Website
- Description: Provider of innovative endovascular catheters, designing, developing, manufacturing, and distributing devices for arterial and venous thromboembolic conditions using mechanical and pharmacological methods. Offerings include BASHIR Endovascular Catheters, BASHIR Plus with an expandable infusion basket for extensive thrombus in peripheral vessels, and BASHIR S-B for shorter peripheral and pulmonary vessels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Thrombolex company profile →
CryoTherapeutics
HQ: Belgium
Website
- Description: Provider of a proprietary intracoronary cryotherapy system (CTS) for the treatment of coronary artery disease, designed to stabilize high-risk plaque lesions and potentially prevent heart attacks without leaving a stent. Offerings include a patented catheter and console interface for localized cryoenergy delivery, and ongoing clinical trials, including the POLARSTAR study, to demonstrate safety and efficacy for regulatory approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CryoTherapeutics company profile →
Field Medical
HQ: United States
Website
- Description: Provider of pulsed field ablation (PFA) technologies that use micro-bursts of energy delivered via catheter to disrupt cardiac cells without heat or cold, aiming to improve cardiac ablation treatments. Offerings include FieldForce Ventricular PFA for ventricular arrhythmia ablation, currently in first-in-human trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Field Medical company profile →
Bardy Diagnostics
HQ: United States
Website
- Description: Provider of cardiac monitoring and arrhythmia detection solutions, including the CAM Patch, a lightweight, extended-wear cardiac patch that optimizes P-wave capture for up to 14 days of continuous ECG monitoring; the BDxCONNECT Portal for secure ECG data upload, analysis, and full report delivery; and the CAM Report offering clear, full-disclosure ECG interpretations typically within 48 hours. CAM can be worn during exercise or while showering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bardy Diagnostics company profile →
CardioFocus
HQ: United States
Website
- Description: Provider of cardiac ablation technologies, including the HeartLight X3 laser balloon catheter for pulmonary vein isolation in atrial fibrillation with direct visualization, titratable laser energy, and compliant balloon technology, and the CENTAURI system leveraging Pulsed Electric Field for intracardiac ablation, compatible with existing mapping systems and focal ablation catheters.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CardioFocus company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Angiolink
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Angiolink
2.2 - Growth funds investing in similar companies to Angiolink
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Angiolink
4.2 - Public trading comparable groups for Angiolink
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →